• Vaccine Name: Multivalent immunotherapeutic vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004616
• Type: multivalent
• Status: Research
• Antigen: MART-1, gp100 (Pmel17), NY-ESO-1, MAGE-A1, tyrosinase, TRP-1 (gp75), TRP-2, CD146 and CD71, melanotransferrin
• MLANA gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Suriano et al., 2013)
  • Detailed Gene Information: Click Here.
• MAGEA1-Duplicate gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Suriano et al., 2013)
  • Detailed Gene Information: Click Here.
• gp100 (PMEL) gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Suriano et al., 2013)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion (Suriano et al., 2013).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: gp100 was only expressed by GLM-2 while the cancer testis antigen, NY-ESO-1, was only expressed by 3MM, all of the primary cells expressed tyrosinase, TRP-1, and TRP-2, The cell surface antigens, CD71 and CD146, were expressed by all of the primary cells except for
  GLM-2, which did not express CD71, melanotransferrin
  (p97), was only expressed by MEL-2 (Suriano et al., 2013).